Fresenius Kabi

Type
Internal restructuring
Country
World
Region
Location of affected unit(s)
Germany, other locations
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.1 - Manufacture of basic pharmaceutical products
2,000 jobs
Number of planned job losses
Job loss
Announcement Date
2 June 2022
Employment effect (start)
2 June 2022
Foreseen end date

Description

German pharmaceutical company Fresenius has announced that it will cut about 2,000 jobs worldwide.

So far, the company has revealed that 250 positions are expected to be cut in Germany Fresenius Kabi 2022-DE. The layoffs are part of a global efficiency programme and will be carried out at the company’s drug and nutrition division, Fresenius Kabi.

Fresenius provides products and services for dialysis, in hospitals and in outpatient medical care.

In November 2021, the dialysis subsidiary Fresenius Medical Care had already announced the reduction of 5000 jobs worldwide[Fresenius Medical Care-2021-WO] (https://apps.eurofound.europa.eu/restructuring-events/detail/106120).

Sources

Citation

Eurofound (2022), Fresenius Kabi , Internal restructuring in World, factsheet number 201683, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/201683.